BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GlaxoSmithKline (GSK) Receives Approvable Letter For Topical Antibiotic, Altabax(TM) (retapamulin ointment), 1%


12/26/2006 3:57:17 AM

PHILADELPHIA--(BUSINESS WIRE)--GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration has issued an approvable letter for its topical antibacterial, Altabax (retapamulin ointment), 1%, for the treatment of secondarily-infected traumatic lesions (SITL). SITL is a type of skin and skin structure infection most commonly caused by Staphylococcus aureus and Streptococcus pyogenes.

In the letter to GSK, the FDA requested additional information to complete its assessment of Altabax as a treatment for SITL; no safety concerns were noted. GSK intends to respond in full to the FDA's requests and work with the agency to pursue approval of Altabax for the treatment of SITL.

The FDA also notified GSK that it did not approve a second indication, for the treatment of secondarily-infected dermatoses (SID), in the same New Drug Application (NDA). The FDA will require additional clinical studies to consider approving Altabax as a treatment for SID. GSK is currently in discussions with the FDA regarding these studies.

A separate Altabax NDA for the treatment of impetigo is also currently being reviewed by the FDA. Impetigo is a superficial skin infection most commonly seen in children. The NDA for the impetigo indication is based primarily on the results of a double-blind, placebo-controlled clinical study demonstrating that the efficacy of Altabax was superior to placebo in adults and children. GSK expects to receive the FDA's decision for this indication in 2Q 2007.

Retapamulin belongs to a new class of antibiotics called pleuromutilins and demonstrates a unique mode of action that is different from currently available antibiotics. Due to this unique mode of action, retapamulin exhibits a low potential for the development of resistance in vitro.

GlaxoSmithKline has an established heritage in the development of novel anti-infectives to meet clinical needs. These products include the topical antibacterial agent Bactroban® (mupirocin) as well as the oral agent Augmentin® (amoxicillin/clavulanate potassium). GlaxoSmithKline, one of the world's leading research-based pharmaceutical and healthcare companies, is committed to improving the quality of human life by enabling people to do more, feel better and live longer. Additional information about GlaxoSmithKline can be found online at www.gsk.com.

Contact:

GlaxoSmithKline Robert Perry, 919-483-2839 Mobile: 407-492-4616

Source: GlaxoSmithKline

>>> Discuss This Story



Read at BioSpace.com
Read at AP

BioSpace.com
AP
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES